© 2022 MJH Life Sciences and AJMC. All rights reserved.
© 2022 MJH Life Sciences™ and Clinical Care Targeted Communications, LLC. All rights reserved.
Jason Starr, DO, discusses the importance of molecular residual disease within the cancer treatment landscape.
December 22nd 2021
Jason Starr, DO, provides an overview of molecular residual disease (MRD) in the hematological and oncological treatment landscapes.
Jason Starr, DO, explains circulating tumor DNA’s (ctDNA) role in oncology and its role in MRD.